VONTOBEL FINANCIAL PRODUCTS GMBH | Market Closed - Borsa Italiana 11:44:59 2024-07-11 am EDT | ||
| 1,062 EUR | +1.58% |
|
| Current month | -0.47% | ||
| 1 month | -4.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 1,062 | +1.58% |
| 24-07-10 | 1,046 | 0.00% |
| 24-07-09 | 1,046 | -0.38% |
| 24-07-08 | 1,050 | -0.19% |
| 24-07-05 | 1,052 | +0.10% |
Real-time Borsa Italiana
Last update July 11, 2024 at 11:44 am EDT
More quotesStatic data
| Product type | Other Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| F43506 | |
| ISIN | DE000VM8RPN6 |
| Date issued | 2024-01-24 |
| Maturity | 2026-01-26 (564 Days) |
| Parity | 0.1 : 1 |
| Emission price | 996 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,132 € |
|---|---|
| Lowest since issue | 896.5 € |
| Spread | 15 € |
| Spread % | 1.40% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.4
USD
Average target price
145.9
USD
Spread / Average Target
+24.19%
- Stock Market
- Certificates
- F43506 Certificat
